{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:18Z","timestamp":1761059538731},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:00:00Z","timestamp":1369872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40262-013-0078-1","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T12:44:05Z","timestamp":1369831445000},"page":"885-896","source":"Crossref","is-referenced-by-count":24,"title":["The Relationship Between Fluticasone Furoate Systemic Exposure and Cortisol Suppression"],"prefix":"10.1007","volume":"52","author":[{"given":"Ann","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,30]]},"reference":[{"key":"78_CR1","unstructured":"L\u00f6tvall J, Bakke P, Bjermer L, et al. Safety and efficacy of fluticasone furoate\/vilanterol trifenatate (FF\/VI) in COPD patients. Eur Respir J 2010;24:1013s."},{"issue":"Suppl. 55","key":"78_CR2","first-page":"138s","volume":"38","author":"R Kempsford","year":"2011","unstructured":"Kempsford R, Allen A, Bareille P, et al. The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. Eur Respir J. 2011;38(Suppl. 55):138s.","journal-title":"Eur Respir J"},{"key":"78_CR3","doi-asserted-by":"crossref","first-page":"e000370","DOI":"10.1136\/bmjopen-2011-000370","volume":"2","author":"J L\u00f6tvall","year":"2012","unstructured":"L\u00f6tvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of 4\u00a0weeks\u2019 treatment with combined fluticasone furoate\/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open. 2012;2:e000370.","journal-title":"BMJ Open"},{"issue":"Suppl. 56","key":"78_CR4","first-page":"P2092","volume":"40","author":"WW Busse","year":"2012","unstructured":"Busse WW, O\u2019Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma. Eur Respir J. 2012;40(Suppl. 56):P2092.","journal-title":"Eur Respir J"},{"key":"78_CR5","doi-asserted-by":"crossref","unstructured":"Boscia JA, Pudi KK, Zvarich MT, et al. Effect of fluticasone furoate (FF)\/vilanterol (VI) administered once daily on 24\u00a0h pulmonary function in patients with COPD: a randomized, three-way, incomplete block, cross-over study. Am J Resp Crit Care Med. 2012;185(Meeting abstracts):A2939.","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2939"},{"issue":"Suppl. 56","key":"78_CR6","first-page":"P2889","volume":"40","author":"A Agusti","year":"2012","unstructured":"Agusti A, De Backer W, De Teresa L, et al. Efficacy of combination fluticasone furoate\/vilanterol (FF\/VI) and salmeterol\/fluticasone propionate (SFC) over 12\u00a0weeks in patients with COPD. Eur Respir J. 2012;40(Suppl. 56):P2889.","journal-title":"Eur Respir J"},{"issue":"Suppl. 56","key":"78_CR7","first-page":"P2091","volume":"40","author":"ER Bleecker","year":"2012","unstructured":"Bleecker ER, L\u00f6tvall J, O\u2019Bryne PM, et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12\u00a0weeks in patients with persistent asthma. Eur Respir J. 2012;40(Suppl. 56):P2091.","journal-title":"Eur Respir J"},{"issue":"Suppl. 56","key":"78_CR8","first-page":"P1794","volume":"40","author":"PM O\u2019Byrne","year":"2012","unstructured":"O\u2019Byrne PM, Bleecker ER, Bateman ED, et al. Efficacy and safety of fluticasone furoate (FF)\/vilanterol (VI) once daily (OD) for 24\u00a0weeks in persistent asthma. Eur Respir J. 2012;40(Suppl. 56):P1794.","journal-title":"Eur Respir J"},{"key":"78_CR9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/thx.52.5.476","volume":"52","author":"BJ Lipworth","year":"1997","unstructured":"Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997;52:476\u201382.","journal-title":"Thorax"},{"key":"78_CR10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archinte.159.9.941","volume":"159","author":"BJ Lipworth","year":"1999","unstructured":"Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systemic review and meta-analysis. Arch Intern Med. 1999;159:941\u201355.","journal-title":"Arch Intern Med"},{"key":"78_CR11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1081-1206(10)60683-7","volume":"98","author":"DI Bernstein","year":"2007","unstructured":"Bernstein DI, Allen DB. Evaluation of tests of hypothalamic\u2013pituitary\u2013adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007;98:118\u201327.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"78_CR12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1183\/09031936.06.00119305","volume":"28","author":"M Masoli","year":"2006","unstructured":"Masoli M, Weatherall M, Holt S, et al. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006;28:960\u20137.","journal-title":"Eur Respir J"},{"key":"78_CR13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/thx.51.3.262","volume":"51","author":"DJ Clark","year":"1996","unstructured":"Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996;51:262\u20136.","journal-title":"Thorax"},{"key":"78_CR14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000216193","volume":"16","author":"FM Bruni","year":"2009","unstructured":"Bruni FM, De Luca G, Venturoli V, et al. Intranasal corticosteroids and adrenal suppression. NeuroImmunoModulation. 2009;16:353\u201362.","journal-title":"NeuroImmunoModulation"},{"key":"78_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1526-0542(03)00029-0","volume":"4","author":"S Crowley","year":"2003","unstructured":"Crowley S. Inhaled glucocorticoids and adrenal function: an update. Paediatr Respir Rev. 2003;4:153\u201361.","journal-title":"Paediatr Respir Rev"},{"key":"78_CR16","doi-asserted-by":"crossref","unstructured":"Bleecker ER, Bateman ED, Busse WW, et al. Consistently favorable safety profile of fluticasone furoate (FF), a once-daily (OD) inhaled corticosteroid (ICS), across a range of treatment steps in patients with uncontrolled asthma. AJRCCM. 2011;183:A1300 (Abstract).","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A1300"},{"key":"78_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/thoraxjnl-2011-200308","volume":"67","author":"WW Busse","year":"2012","unstructured":"Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012;67:35\u201341.","journal-title":"Thorax"},{"key":"78_CR18","unstructured":"Beal SL, Sheiner LB. NONMEM users guides, Version 5. NONMEM Project Group, University of California, San Francisco. 1996."},{"key":"78_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"78_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185\u2013202.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"78_CR21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0026-0495(74)90118-8","volume":"23","author":"RE Juselius","year":"1974","unstructured":"Juselius RE, Kenny FM. Urinary free cortisol excretion during growth and aging: correlation with cortisol production rate and 17-hydroxycorticosteroid excretion. Metabolism. 1974;23:847\u201352.","journal-title":"Metabolism"},{"issue":"Suppl. 1","key":"78_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200039001-00007","volume":"39","author":"AE Mackie","year":"2000","unstructured":"Mackie AE, Bye A. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers. Clin Pharmacokinet. 2000;39(Suppl. 1):47\u201354.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 1","key":"78_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003088-200039001-00006","volume":"39","author":"PT Daley-Yates","year":"2000","unstructured":"Daley-Yates PT, Tournant J, Kunka RL. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet. 2000;39(Suppl. 1):39\u201345.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-013-0078-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0078-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0078-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T06:51:05Z","timestamp":1563087065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-013-0078-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,30]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s40262-013-0078-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,30]]}}}